These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 32983128)

  • 1. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
    Kramer ED; Abrams SI
    Front Immunol; 2020; 11():1963. PubMed ID: 32983128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
    Qu P; Wang LZ; Lin PC
    Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developmental pathways of myeloid-derived suppressor cells in neoplasia.
    Abrams SI
    Cell Immunol; 2021 Feb; 360():104261. PubMed ID: 33373817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
    Cai J; Cui Y; Yang J; Wang S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.
    Abrams SI; Netherby CS; Twum DY; Messmer MN
    J Interferon Cytokine Res; 2016 Jul; 36(7):442-53. PubMed ID: 27379866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
    Netherby CS; Abrams SI
    Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
    Adah D; Hussain M; Qin L; Qin L; Zhang J; Chen X
    Pharmacol Res; 2016 Aug; 110():25-34. PubMed ID: 27157248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD205
    Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
    Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-Derived Suppressor Cells.
    Gabrilovich DI
    Cancer Immunol Res; 2017 Jan; 5(1):3-8. PubMed ID: 28052991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.
    Oliver L; Alvarez R; Diaz R; Valdés A; Colligan SH; Nemeth MJ; Twum DYF; Fernández A; Fernández-Medina O; Carlson LM; Yu H; Eng KH; Hensen ML; Rábade-Chediak ML; Fernández LE; Lee KP; Perez L; Muhitch JB; Mesa C; Abrams SI
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36150744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives.
    Safari E; Ghorghanlu S; Ahmadi-Khiavi H; Mehranfar S; Rezaei R; Motallebnezhad M
    J Cell Physiol; 2019 Jul; 234(7):9966-9981. PubMed ID: 30537008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
    Zhang Y; Guoqiang L; Sun M; Lu X
    Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
    Ostrand-Rosenberg S; Fenselau C
    J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasticity of myeloid-derived suppressor cells in cancer.
    Tcyganov E; Mastio J; Chen E; Gabrilovich DI
    Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
    Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
    Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers.
    Lim HX; Kim TS; Poh CL
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.